102 related articles for article (PubMed ID: 18698169)
1. ErbB4 targeting approaches for prostate cancer treatment.
Wheeler DL; Rangnekar VM; Schwarze SR
Cancer Biol Ther; 2008 Jul; 7(7):1095-7. PubMed ID: 18698169
[No Abstract] [Full Text] [Related]
2. Anti-ERBb4 targeted therapy combined with radiation therapy in prostate cancer. Results of in vitro and in vivo studies.
Vexler A; Lidawi G; Loew V; Barnea I; Karaush V; Lev-Ari S; Shtabsky A; Ben-Yosef R
Cancer Biol Ther; 2008 Jul; 7(7):1090-4. PubMed ID: 18443429
[TBL] [Abstract][Full Text] [Related]
3. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma.
Prewett M; Rockwell P; Rockwell RF; Giorgio NA; Mendelsohn J; Scher HI; Goldstein NI
J Immunother Emphasis Tumor Immunol; 1996 Nov; 19(6):419-27. PubMed ID: 9041461
[TBL] [Abstract][Full Text] [Related]
4. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody.
Muthumani K; Marnin L; Kudchodkar SB; Perales-Puchalt A; Choi H; Agarwal S; Scott VL; Reuschel EL; Zaidi FI; Duperret EK; Wise MC; Kraynyak KA; Ugen KE; Sardesai NY; Joseph Kim J; Weiner DB
Cancer Immunol Immunother; 2017 Dec; 66(12):1577-1588. PubMed ID: 28819703
[TBL] [Abstract][Full Text] [Related]
5. Effect of combining anti-epidermal growth factor receptor antibody C225 and radiation on DU145 prostate cancer.
Wagener M; Zhang X; Villarreal HG; Levy L; Allen P; Shentu S; Fang B; Krishnan S; Chang JY; Cheung MR
Oncol Rep; 2008 May; 19(5):1071-7. PubMed ID: 18425360
[TBL] [Abstract][Full Text] [Related]
6. Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.
Kinoshita Y; Kuratsukuri K; Newman N; Rovito PM; Kaumaya PT; Wang CY; Haas GP
Prostate Cancer Prostatic Dis; 2005; 8(4):359-63. PubMed ID: 16172607
[TBL] [Abstract][Full Text] [Related]
7. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
[TBL] [Abstract][Full Text] [Related]
8. [Combined anti-EGFR and anti-HER2 monoclonal antibodies: preclinical efficacy in the treatment of pancreatic cancer].
Larbouret C; Robert B; Teulon I; Azria D; Pèlegrin A
Med Sci (Paris); 2007 Oct; 23(10):800-3. PubMed ID: 17937885
[No Abstract] [Full Text] [Related]
9. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
10. Targeting ErbB-1 and ErbB-4 in irradiated head and neck cancer: results of in vitro and in vivo studies.
Barnea I; Haif S; Keshet R; Karaush V; Lev-Ari S; Khafif A; Shtabsky A; Yarden Y; Vexler A; Ben Yosef R
Head Neck; 2013 Mar; 35(3):399-407. PubMed ID: 22367849
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
[TBL] [Abstract][Full Text] [Related]
12. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.
Cappuccini F; Stribbling S; Pollock E; Hill AV; Redchenko I
Cancer Immunol Immunother; 2016 Jun; 65(6):701-13. PubMed ID: 27052571
[TBL] [Abstract][Full Text] [Related]
14. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
15. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer: Towards effective combination of ADT and immunotherapy.
Thoma C
Nat Rev Urol; 2016 Jun; 13(6):300. PubMed ID: 27112389
[No Abstract] [Full Text] [Related]
18. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.
Davol PA; Smith JA; Kouttab N; Elfenbein GJ; Lum LG
Clin Prostate Cancer; 2004 Sep; 3(2):112-21. PubMed ID: 15479495
[TBL] [Abstract][Full Text] [Related]
19. [Immunotherapy of prostate cancer].
Schulze H; Sommerfeld HJ
Urologe A; 1993 Sep; 32(5):382-9. PubMed ID: 8212423
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications.
Milenic DE; Wong KJ; Baidoo KE; Ray GL; Garmestani K; Williams M; Brechbiel MW
Cancer Biother Radiopharm; 2008 Oct; 23(5):619-31. PubMed ID: 18999934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
